Trending Across touchONCOLOGY

At a glance: education, conference reports and articles

More From Education

View All

Learn more from touchONCOLOGY with independent learning activities

Haematological Malignancies, Immunotherapy, Leukaemia, Lymphoma
touchEXPERT OPINIONS
Optimizing care with CAR T-cell therapy now and in the future for patients with B-cell malignancies
Prof. Catherine Thieblemont, Prof. Dr. Marion Subklewe, Dr Maeve O’Reilly, Prof. Adriana Balduzzi, Dr Michael Dickinson Watch Time: 58 mins Available in:

Get an update on chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies, including guidance on referral and toxicity management, in these interviews with five experts.

Learning objectives
Learning Objectives
  • Recall the latest clinical trial and real-world data for CAR T-cell therapies in the management of B-cell malignancies
  • Describe which patients are eligible for CAR T-cell therapy and discuss the optimal time for referral
  • Discuss the safety profile of CAR T-cell therapy and the associated management strategies
  • Describe data for new and emerging indications for CAR T-cell therapy
Lung Cancer
touchEXPERT OPINIONS
Progress in EGFR-mutant NSCLC: Where are we going?
Dr Raffaele Califano, Dr Lecia Sequist, Prof. Yi-Long Wu Watch Time: 36 mins Available in:

Watch leading non-small cell lung cancer (NSCLC) experts discuss the current standard and the latest advancements in epithelial growth factor receptor (EGFR)-targeted therapy.

Learning objectives
Learning Objectives
  • Describe the rationale for and clinical trial data associated with combination therapy in first-line EGFR-mutant NSCLC
  • Describe the mechanisms of resistance to third-generation EGFR-TKIs and strategies to manage drug resistance in the second-line setting
  • Recall data on emerging therapeutic strategies for early-stage EGFR-mutant NSCLC and how this may impact the metastatic treatment landscape

    • More From The Conference Hub

    View All

    View highlights and coverage from leading international Oncology congresses

    Latest Journal Articles

    View All

    Read the latest articles from our peer reviewed Oncology journals published by touchONCOLOGY

    Haematology
    FOREWORD – ONCOLOGY & HEMATOLOGY (US) – VOLUME 16 ISSUE 2– FALL 2020

    Welcome to the latest edition of Oncology & Hematology Review, which contains a wide range of articles reflecting the scope of this field. We begin with an article on the subject of urothelial cancer, whose treatment landscape has been transformed in recent years by the availability of immune checkpoint inhibitors. Williams et al. review the role […]

    Sarcoma
    Pexidartinib and CSF1R inhibitors As Treatment for Tenosynovial Giant Cell Tumors
    Caroline J Granger, Ty Subhawong, Gina D’Amato

    Oncology & Hematology Review (US). 2020;16(2):119-23 DOI: https://doi.org/10.17925/OHR.2021.16.2.119

    Tenosynovial giant cell tumor (TGCT)—previously referred to as giant cell tumor of the tendon sheath or pigmented villonodular synovitis (PVNS)—is a largely benign, rare, proliferative lesion arising from the synovial lining of joints, bursae, and tendon sheaths.1 This review serves to discuss the epidemiology, molecular biology, clinical behavior, and the current treatment modalities of TGCT that […]

    Multiple Myeloma
    Latest Developments in Cellular Therapy for Multiple Myeloma
    Tara K Gregory, Henning Schade, Jesús G Berdeja

    Oncology & Hematology Review (US). 2020;16(2):111-8 DOI: https://doi.org/10.17925/OHR.2021.16.2.111

    Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical advances, including novel drugs and continuous therapy with treatment sequencing, have improved survival statistics.2 Despite this, MM remains largely incurable and the relapsed/refractory population remains vulnerable […]

    Gastrointestinal Oncology
    Nivolumab for the Treatment of Esophageal Squamous Cell Carcinoma
    Mao Okada, Shun Yamamoto, Ken Kato

    Oncology & Hematology Review. 2020;16(2):90–4 DOI: https://doi.org/10.17925/OHR.2021.16.2.90

    Esophageal cancer is the seventh most common malignancy and the sixth leading cause of death from cancer worldwide.1 The main histological subtypes are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC is the most common subtype, and the frequency of this disease is highest in Eastern Asia and Eastern Africa.2 In Western countries, however, the incidence […]

    Want To Know More About Our Journals?

    Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journals we produce.

    The European Oncology & Haematology and Oncology & Hematology Review (US) are free-to-access, peer reviewed journals that aim to provide balanced and objective articles relevant to the day-to-day clinical setting.

    Learn more about our journals

    Society & Congress Partners

    View All

    touchONCOLOGY is proud to partner with leading medical societies and congresses from around the world to bring you news and insight from virtual and live events
    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar